These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1354053)

  • 1. In vivo assessment of dopaminergic variables in schizophrenia.
    Martinot JL; Paillere-Martinot ML; Lecrubier Y; Dao-Castellana MH; Loc'h C; Poirier MF; Allilaire JF; Feline A; Manus A; Aubin F
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():470A-471A. PubMed ID: 1354053
    [No Abstract]   [Full Text] [Related]  

  • 2. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
    Wong DF; Wagner HN; Tune LE; Dannals RF; Pearlson GD; Links JM; Tamminga CA; Broussolle EP; Ravert HT; Wilson AA; Toung JK; Malat J; Williams JA; O'Tuama LA; Snyder SH; Kuhar MJ; Gjedde A
    Science; 1986 Dec; 234(4783):1558-63. PubMed ID: 2878495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine D2 receptors in substantia nigra in schizophrenia.
    Owen R; Owen F; Poulter M; Crow TJ
    Brain Res; 1984 May; 299(1):152-4. PubMed ID: 6144367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients.
    Martinot JL; Peron-Magnan P; Huret JD; Mazoyer B; Baron JC; Boulenger JP; Loc'h C; Maziere B; Caillard V; Loo H
    Am J Psychiatry; 1990 Jan; 147(1):44-50. PubMed ID: 2293788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.
    Coward D; Dixon K; Enz A; Shearman G; Urwyler S; White T; Karobath M
    Psychopharmacol Bull; 1989; 25(3):393-7. PubMed ID: 2576320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 9. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS; Moerlein SM
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Buchsbaum MS
    Neuropsychopharmacology; 1992 Aug; 7(1):67-8; discussion 73-5. PubMed ID: 1355970
    [No Abstract]   [Full Text] [Related]  

  • 11. Elevated D2 dopamine receptors in drug-naïve schizophrenics.
    Zeeberg BR; Gibson RE; Reba RC
    Science; 1988 Feb; 239(4841 Pt 1):789-91. PubMed ID: 2963379
    [No Abstract]   [Full Text] [Related]  

  • 12. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
    Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will new dopamine receptors offer a key to schizophrenia?
    Taubes G
    Science; 1994 Aug; 265(5175):1034-5. PubMed ID: 8066441
    [No Abstract]   [Full Text] [Related]  

  • 14. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Lancet; 1992 Jul; 340(8813):199-202. PubMed ID: 1353135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central dopaminergic mechanisms in schizophrenia.
    Owen F; Crow TJ; Poulter M
    Acta Psychiatr Belg; 1987; 87(5):552-65. PubMed ID: 2897760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 18. Dopamine D2 receptors in schizophrenia studied in vivo.
    Crawley JC; Owens DG; Crow TJ; Poulter M; Johnstone EC; Smith T; Oldland SR; Veall N; Owen F; Zanelli GD
    Lancet; 1986 Jul; 2(8500):224-5. PubMed ID: 2873471
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine and schizophrenia--proof at last?
    Harrison PJ
    Lancet; 2000 Sep; 356(9234):958-9. PubMed ID: 11041394
    [No Abstract]   [Full Text] [Related]  

  • 20. Schizophrenia as a brain disease. The dopamine receptor story.
    Seeman P
    Arch Neurol; 1993 Oct; 50(10):1093-5. PubMed ID: 8215969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.